David Aaron Lehman, General Counsel at Pulmonx Corp (NASDAQ:LUNG), recently sold a total of 5,497 shares of the company's common stock. The transactions took place on December 2, with shares sold at prices ranging from $6.18 to $6.19 each, below the current trading price of $6.53. Lehman's sales were conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted between 2021 and 2024. According to InvestingPro analysis, Pulmonx maintains a strong financial position, holding more cash than debt on its balance sheet.
The sales included 410 shares at $6.18 each, totaling $2,533, and 722 shares at $6.19 each, totaling $4,469. Additionally, 2,755 shares were sold at $6.19 each, amounting to $17,053, while 1,610 shares were sold at $6.18 each, totaling $9,949. Following these transactions, Lehman holds 197,851 shares directly in the $258.25 million market cap company. InvestingPro subscribers can access detailed insights about Pulmonx's valuation, financial health score, and comprehensive analysis in the Pro Research Report, along with additional ProTips about the company's future prospects.
In other recent news, Pulmonx Corporation reported a 15% year-over-year increase in Q3 worldwide sales, totaling $20.4 million. The U.S. market notably contributed with a 17% surge in revenue, while international sales also saw a 12% growth. The company reaffirmed its full-year revenue guidance, projecting continued growth, especially in international markets. Pulmonx is strategically focusing on physician training, patient workflow automation, and raising awareness of its Zephyr Valves for COPD treatment. Despite a reported net loss of $14.1 million for the quarter, the company managed to reduce its operating expenses by around $5 million, maintaining a stable gross margin of 74%. The firm's management anticipates growth catalysts in 2025 and beyond, with the AeriSeal program set for commercial launch outside the U.S. in 2026 and within the U.S. in 2027. These recent developments underline Pulmonx's resilience and strategic foresight in its performance and growth strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.